$1.6M
+$1.6M this year1 filing since 2026 · latest Other filed
Biolexis Therapeutics is a clinical-stage biopharmaceutical company in Lehi, Utah, developing oral small-molecule therapies for metabolic disease. Its lead programs are a first-in-class allosteric GLP-1 receptor agonist and a first-in-class AMPK activator, designed to deliver injectable-level efficacy in a daily pill with better tolerability. The company uses an AI-driven discovery platform, MolecuLern, that optimizes for oral bioavailability, tolerability, and low drug-drug interaction risk from the earliest stages of design. It was founded in 2021 by David J. Bearss and Hariprasad Vankayalapati.
What sets it apart
Designs oral GLP-1 and AMPK drugs for tolerability from the start: BLX-7006 reported 0% GI-related discontinuation in Phase 1 and BLX-0871 showed no cardiac biomarker abnormalities, addressing the two failure modes that have limited injectable GLP-1s and prior AMPK programs.
A first-in-class allosteric oral GLP-1 receptor agonist for obesity and type 2 diabetes, which has completed a first-in-human Phase 1 trial.
